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γ-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the central nervous
system, and disturbances in the GABAergic system have been implicated in numerous neu-
rological and neuropsychiatric diseases. The GABAB receptor is a heterodimeric class C G
protein-coupled receptor (GPCR) consisting of GABAB1a/b and GABAB2 subunits. Two
GABAB receptor ligand binding sites have been described, namely the orthosteric GABA
binding site located in the extracellular GABAB1 Venus fly trap domain and the allosteric
binding site found in the GABAB2 transmembrane domain. To date, the only experimentally
solved three-dimensional structures of the GABAB receptor are of the Venus fly trap domain.
GABAB receptor allosteric modulators, however, show great therapeutic potential, and eluci-
dating the structure of the GABAB2 transmembrane domain may lead to development of
novel drugs and increased understanding of the allosteric mechanism of action. Despite
the lack of x-ray crystal structures of the GABAB2 transmembrane domain, multiple crystal
structures belonging to other classes of GPCRs than class A have been released within
the last years. More closely related template structures are now available for homology
modelling of the GABAB receptor. Here, multiple homology models of the GABAB2 subunit
of the GABAB receptor have been constructed using templates from class A, B and C
GPCRs, and docking of five clusters of positive allosteric modulators and decoys has been
undertaken to select models that enrich the active compounds. Using this ligand-guided
approach, eight GABAB2 homology models have been chosen as possible structural repre-
sentatives of the transmembrane domain of the GABAB2 subunit. To the best of our knowl-
edge, the present study is the first to describe homology modelling of the transmembrane
domain of the GABAB2 subunit and the docking of positive allosteric modulators in the
receptor.
Introduction
G-protein coupled receptors (GPCRs) belong to a superfamily of integral membrane proteins
that are activated by a formidable variety of ligands–from photons and ions to neurotransmitters,
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lipids and peptides—and hence are involved in the regulation of a wide variety of cellular and
physiological functions. Members of the GPCR superfamily are characterised by a canonical
seven α-helical transmembrane (7TM) domain topology and their activation of cytoplasmic
guanine nucleotide-binding proteins (G-proteins) upon receptor activation. However, there is
great variability in both amino acid sequence and functional coupling among the> 800 human
GPCR sequences (i.e., approx. 2% of the human genome) that have been identified [1]. Using
exhaustive phylogenetic analysis, the GPCRs have been classified into the Glutamate (22 recep-
tors), Rhodopsin (~680 receptors– 284 non-olfactory, ~380 olfactory), Adhesion (33 receptors),
Frizzled (11 receptors), and Secretin (15 receptors), and Others (>40 receptors) families (the
GRAFS classification system) [2,3]. The Rhodopsin, Secretin, Glutamate and Frizzled families
also correspond to the class A, B, C, and F GPCRs, respectively, in the A-F classification system
[4]. Until very recently, the only available x-ray crystal structure templates for homology model-
ling of the 7TM domain of GPCRs belonged to class A GPCRs. Within the last years, however,
the number of experimentally solved GPCR structures have increased significantly, and x-ray
crystal structures of nearly 40 unique GPCRs, including class B, C and F GPCRs, have now been
released [5,6].
The GABAB receptor is a class C GPCR and one of three native receptors of γ-aminobutyric
acid (GABA), the other two being the ionotropic GABAA and GABAC receptors. The GABAB
receptor is located in both pre- and postsynaptic inhibitory and excitatory synapses as well as
in perisynaptic and extrasynaptic plasma membranes [7]. While activation of postsynaptic
GABAB receptors results in opening of G-protein-coupled inwardly-rectifying potassium
(GIRK) channels, hyperpolarising potassium conductance and direct inhibition of postsynap-
tic calcium channels, activation of presynaptic GABAB activation results in reduction of neuro-
transmitter release, primarily through the inhibition of calcium-dependent neurotransmitter
release [7]. GABA is the main inhibitory neurotransmitter of the central nervous system
(CNS), and GABAergic inhibitory interneurons play pivotal roles in the process of cortical
inhibition by attenuating the activities of other cortical neurons, in particular, the excitatory
pyramidal neurons, and by generating inhibitory post-synaptic potentials (IPSPs) that modu-
late cortical excitability and neural plasticity [8]. Disturbances in the GABAergic system have
been implicated in numerous neurological and neuropsychiatric disorders, including anxiety
and depression, epilepsy, autism spectrum disorders, drug addiction, and schizophrenia, as
well as other conditions such as muscle spasticity, gastrointestinal reflux disorder, and pain
[9,10].
The GABAB receptor is a functional heterodimer consisting of GABAB1a/b and GABAB2
subunits [10]. A schematic illustration of the receptor is shown in Fig 1. Each subunit consists
of three distinct domains, the N-terminal, extracellular domain, also known as the Venus fly
trap (VFT) domain, the 7TM domain characteristic of all GPCRs, and the intracellular C-ter-
minal tail [10]. The cysteine-rich domain (CRD) linking the VTF to the 7TM bundle in other
class C members is absent in the GABAB receptor [11]. Two GABAB receptor ligand-binding
sites have been characterised. The orthosteric binding site recognised by GABA and other
agonists and antagonists is located within the extracellular VTF domain of the GABAB1 sub-
unit [10]. To date, the only GABAB receptor x-ray crystal structures available are of the VTF
domain [12]. Likewise, the only currently marketed GABAB receptor drug is the orthosteric
agonist baclofen, a muscle relaxant and antispastic agent; however, the therapeutic use of bac-
lofen is limited due to its low CNS permeability, short duration of action, narrow therapeutic
window, and rapid tolerance [10].
The GABAB receptor allosteric binding site has been mapped to the 7TM domain of GABAB2
receptor subunit (Fig 1) [13,14]. Binding of ligands to allosteric sites of GPCRs may cause recep-
tor conformational changes that positively or negatively impact the affinity (association and/or
Allosteric modulation of the GABAB receptor
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dissociation rates) or the efficacy (intracellular responses) of the orthosteric ligand [15]. As allo-
steric modulators acting through affinity or efficacy modulation exert their effects only upon
binding of an orthosteric agonist, they hence provide a fine-tuning of the physiological signal
rather than turning the signal on or off themselves. Allosteric binding sites are also often less
conserved than the orthosteric binding sites of homologous GPCRs, and allosteric modulators
thus may act more selectively and potentially cause fewer side effects than orthosteric ligands.
Due to their non-competitive mode of action, lower dosages of the ligands may also be
Fig 1. Schematic representation of the GABAB1 (grey) and GABAB2 (blue) subunits of the GABAB
receptor. X-ray crystal structure of extracellular VFT domain in complex with the antagonist CGP46381 (PDB
id 4MS1) (ribbon representation), 7TM domain (cylinder representation) with the PAM ADX71943
representing the allosteric binding pocket, and intracellular C-terminal domain with the coil-coil interaction, are
shown.
https://doi.org/10.1371/journal.pone.0173889.g001
Allosteric modulation of the GABAB receptor
PLOS ONE | https://doi.org/10.1371/journal.pone.0173889 March 21, 2017 3 / 21
administered to obtain the desired pharmacological effect, further reducing the risks of adverse
side effects. GABAB receptor studies have shown that receptor desensitisation and down-regula-
tion is less likely to occur with positive GABAB allosteric modulators than with orthosteric ago-
nists, and have also indicated that positive allosteric modulators may be devoid of the adverse
effects of the agonist baclofen [16]. Currently, only a limited number of GABAB receptor
positive allosteric modulators (PAMs), which act by enhancing the potency and efficacy of
GABAB receptor orthosteric ligands, have been identified (S1 Table). The first GABAB receptor
PAMs discovered were the di-tert-butylbenzenes and pyrimidines CGP7930 and GS39783
and their analogues, reported in 2001 and 2003 [17,18]. More lately, the thiophenes COR627,
COR628 and analogues, and the structurally unrelated ADX71943 and analogues, have been
shown to be GABAB receptor PAMs [19,20]. In 2016, the structurally novel compound SSD114
was also shown to be a GABAB receptor PAM [21]. The PAM ADX71441, whose structure first
recently was disclosed [22], has moreover been granted regulatory approval to start Phase I clini-
cal trials, where it will be investigated for therapeutic use in Charcot-Marie-Tooth Type 1A dis-
ease (CMT1A), alcohol use disorder, and nicotine dependence [23]. In addition, three analogues
of the di-tert-butylbenzene PAMs were recently also identified as negative allosteric modulators
(NAMs) of the GABAB receptor, acting by decreasing the efficacy of the orthosteric ligands
[24,25].
To gain a deeper understanding of the molecular mechanism of action of allosteric modula-
tion of the GABAB receptor and to aid the discovery of novel allosteric modulators of the
receptor, knowledge about the three-dimensional (3D) structure of the allosteric binding site
of the receptor is of crucial importance. In the present study, extensive homology modelling of
the 7TM domain of GABAB2 subunit has been performed using templates from GPCR classes
A, B, and C, followed by docking of GABAB receptor PAMs and decoys to identify models that
enrich the active compounds. This ligand-guided homology modelling approach has resulted
in the selection of a subset of eight different homology models representing the GABAB2 7TM
domain that enrich the GABAB receptor PAMs. By analysing the docking results of the PAMs
in these models using structural interaction fingerprints (SIFt) and site-directed mutagenesis
data, a detailed description of the putative allosteric binding site of the GABAB receptor is
provided.
Methods
A schematic overview of the ligand-guided homology modelling approach used in the current
paper can be found in Fig 2.
Homology modelling
The following six x-ray crystals structures were used as templates for construction of homology
models of the 7TM domain of the GABAB2 subunit: the class A bovine rhodopsin and β2-
adrenergic receptors (β2-AR) (PDB ids 1U19 and 2RH1), the class B human corticotrophin
release factor 1 (CRF1) and glucagon receptors (PDB ids 4K5Y and 4L6R), and the class C
human metabotropic glutamate receptors 1 and 5 (mGlu1 and mGlu5, PDB ids 4OR2 and
4OO9). The rhodopsin and β2-AR x-ray crystal structures were included as templates for
modelling of GABAB2 as they previously have been successfully used to model class C GPCRs
[26–29]. In addition, two recently released class B x-ray crystal structures that shared approx.
the same template-target sequence identity as the rhodopin-GABAB2 and β2-AR-GABAB2
were included as templates.
The Schrödinger Maestro multiple sequence viewer (MSV) tool [30] was used to construct
a structure-based alignment of the six selected templates. The template structure TM domains
Allosteric modulation of the GABAB receptor
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were superimposed onto the TM domain of the mGlu1 x-ray crystal structure (PDB id 4OR2),
and the sequences were aligned according to the structure superposition. Guided by the Wu
class C and class A-class C alignments [31], manual adjustments of the template alignment
was then performed to remove helical gaps generated by the structural alignment procedure
and to correct other helical alignments errors. The template structures were then superim-
posed again according to the adjusted sequence alignment.
Following the alignment of the template structures, the amino acid sequences of the human
GABAB1 and GABAB2 subunits (UniProt [32] accession numbers Q9UBS5 and O75899) were
then added to the structure-based alignment, and for each of the six templates, a template-
GABAB2 sequence alignment was extracted. The start and end of the 7TM helices were manu-
ally adjusted to fit the length of the template TMs, and the loops of the template and target
Fig 2. Overview of the ligand-guided homology modelling approach. IFD, induced-fit docking;
BEDROC, Boltzmann-enhanced discrimination of receiver operating characteristic; SIFt, structural interaction
fingerprints.
https://doi.org/10.1371/journal.pone.0173889.g002
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sequences were unaligned, except the regions around the cysteine in extracellular loop 2 (EL2).
The final template-GABAB2 7TM alignments used for construction of the GABAB2 homology
models are found in S1 Fig.
MODELLER software version 9.13 [33] was used to construct and refine the GABAB2
homology models. During model construction, TM6 of the class B-based models was specified
to consist of residues in positions 6.35x35-6.57x57 (GPCR database (GPCRdb) numbering
scheme, see below) to include residues G7066.53x53, A7086.55x55, and S7106.57x57, which have
been shown to be important for PAM binding in the GABAB receptor through site-directed
mutagenesis [14]. Visual inspection of the initial GABAB2 models constructed based on class C
templates also revealed that ELs 1 and 2 were entwined. Due to EL2 containing residue C648
involved in the conserved disulphide bond with C5533.29x29 (TM3), EL1 was not included in
these models. In total, 600 GABAB2 homology models (100 models per template) were gener-
ated. To minimise violations of the spatial constraints, conjugate gradient energy minimiza-
tion followed by MD annealing (iterative steps of heating (to 1300 K) and cooling (to 300 K))
was performed using the refine.very_slow function of Modeller [33].
Ligand-guided model selection
Ligands. 72 unique PAMs were retrieved from the scientific literature and clustered
using MOLDPRINT2D fingerprints, Tanimoto similarity metrics and average cluster linkage
method using Schrödinger Canvas software [34]. Application of Kelly criterion [35] resulted in
17 clusters that were reduced to five distinct chemical clusters by merging the most similar
ligand clusters. Full ligand activity data can be found in S1 Table. Structures of commonly
studied PAMs from each cluster of actives are shown in Fig 3.
A combination of known inactive compounds and property-matched compounds were
used as decoys in the ligand-guided model selection. 51 inactive analogues of the PAMs in
clusters 2 and 3 were identified from the scientific literature (S2 Table) [36,37]. In addition,
2536 property-matched decoys (presumed inactive compounds with similar physicochemical
properties but dissimilar 2D topology compared with the actives) were selected from the ZINC
database [38] using an in-house script that followed the Directory of useful decoys (DUD)
methodology [39]. Merging of the property-based and inactive compounds to one decoy set
yielded PAM:decoy ratios ranging between approx. 1:83 (cluster 4) to approx. 1:431 (cluster 5).
Ligand docking. Prior to docking of the PAMs and decoys, the appropriate ionisation
states at pH 7.4 were assigned to all ligands using Schrödinger Epik [40]. Ligand 3D structures
were generated in Schrödinger Ligprep [41] using the OPLS2005 force field and generating
one low energy ring conformation per ligand. For the PAMs and known inactive compounds,
chiral centres specified in literature were kept while unspecified centres were labelled racemic.
The 600 GABAB2 homology models were prepared for docking using the one-step protein
preparation workflow in Schrödinger Maestro [30] by adding and refining missing hydrogen
atoms and adding the disulphide bridge between C5533.29x29 and C648EL2. GABAB receptor
site-directed mutagenesis data [14] was used to determine the GABAB2 allosteric site into
which the ligands were docked. Receptor grid maps representing the shape and chemical prop-
erties of the binding site were generated using Schrödinger Glide [42] by centring on residue
Y5643.40x40 as amino acids in position 3.40x40 in class C GPCRs correspond to position 3.36 in
the class A GPCRs [5], a well-known protein-ligand interaction position. The corresponding
residues in mGlu1 and mGlu5 crystal structures (S668 and P655, respectively) were also
located in the allosteric binding site of these class C members [31,43,44]. Due to the differences
in relative position between Y5643.40x40 and TM6 of the generated models, an outer grid
box size of 25 Å (class A- and B-based models) or 30 Å (class C-based models) were used in
Allosteric modulation of the GABAB receptor
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the present study to ensure that the aforementioned residues G7066.53x53, A7086.55x55, and
S7106.57x57 were included in the grid maps. An inner grid box size of 10 Å was used in all
models.
Docking of the PAMs and decoys was performed using the Schrödinger Virtual Screening
Workflow tool using Glide Standard Precision (SP) with the OPLS2005 force field [42]. One
pose per ligand was kept for post-docking full force field minimisation (optimisation of ligand
pose geometry followed by recalculation of interaction strength between ligand-protein using
the scaled Coulomb-van der Waals term and the Glide score).
Docking analysis. To analyse the docking results, the Boltzmann-enhanced discrimina-
tion of receiver operating characteristic (BEDROC) method was employed [45]. BEDROC is a
Fig 3. Structures of PAM cluster 1–5 representatives. (A) GS39783 (Cluster 1), (B) 27 (BHF177) (Cluster
2), (C) COR627 (Cluster 3), (D) ADX71943 (Cluster 4), and (E) rac-BHFF (Cluster 5). Cluster 1 Emax range:
20%–78% (11 PAMs), cluster 2 EC50 range: 870–5000 nM (10 PAMs), cluster 3 range of increase (%)
compared to 10μM [GABA]: 5.9%–19% (13 PAMs), cluster 4 EC50 range: <100–1000 nM (32 PAMs), and
cluster 5 EC50 range: 4.6–4600 nM (6 PAMs). Please see S1 Table for full activity data.
https://doi.org/10.1371/journal.pone.0173889.g003
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method that incorporates ’early recognition’ (the α exponent prefactor) to weigh the contribu-
tion of rank to the final score [45]. To calculate the BEDROC score for each homology model
based on the docking of the actives in each cluster versus the decoys, the compounds were
ranked according to their Glide score and an α value of 20.0 was employed to ensure that 80%
of the maximum contribution to the BEDROC score came from the first 8% of the ranked list,
as recommended by Truchon et al. [45].
Induced Fit Docking (IFD). To improve the docking results, the Schrödinger Induced Fit
Docking (IFD) protocol [34] was applied. The input GABAB2-ligand complexes were selected
by ranking the 100 models/template per cluster of actives according to their BEDROC scores
and visually inspecting the docking results of the cluster of actives in each of the top-ranked
models. The model that docked the highest numbers of PAMs, or where the binding mode of
the active PAMs was the most consistent, was chosen. The ligand that best represented the
observed binding mode of the PAMs in each chosen model, or the ligand with the largest vol-
ume, was then selected. As no common binding mode of the actives could be identified in the
homology models based on the human glucagon receptor (PDB id 4L6R), GABAB2 models
based on this template were not included. Hence, 25 GABAB2-ligand complexes (5 clusters of
actives, 5 templates) were used as input for IFD (S3 Table).
For each of the final GABAB2-ligand complexes, the ligand was docked into its original
model and maximum 50 different protein-ligand complexes were generated. Backbone and
side-chain minimisation of the neighbouring residues within 5Å of the ligand in each new
complex was then performed, followed by redocking of the ligand into maximum 20 new pro-
tein structures that were within 30 kcal/mol of the best refined structure. In total, the IFD pro-
tocol resulted in the generation of 456 new models of the GABAB2 subunit.
Two of the top-ranked pre-IFD mGlu5-based models docked all cluster 1 PAMs, but only
in one of the models did the ligands dock completely and consistently into the allosteric site
(results not shown). EL2 of this model was, however, incorrectly folded, and though the loop
was distal to the allosteric ligand site and did not affect the docking orientations, the loop had
a slight impact on the Glide scores (results not shown). Thus, to avoid an improperly folded
loop affecting the scoring of the protein-ligand complexes, the C-terminal part of EL2 (resi-
dues P620-E656) was deleted from the post-IFD cluster 1 mGlu5-based models.
Following IFD, each cluster of PAMs and decoys were docked into the 456 IFD-optimised
models and the docking results were analysed using the BEDROC method as described above.
The results of the BEDROC analysis showed that IFD significantly improved the docking
results and no further optimisation of the complexes were thus performed.
Selection of final models. To select GABAB2 homology models from each cluster of
actives, the 456 IFD-optimised models were ranked according to their BEDROC scores.
Visual inspection of the PAM docking results in the 10 best ranked models or with BEDROC
scores> 0.5 was performed by assessing the location of the PAMs in the binding pocket and
the constancy of the orientations of the actives within each cluster of PAMs (S4 Table). Due to
the low BEDROC scores obtained (BEDROC < 0.5; S4 Table), none of the models based on
docking of the cluster 3 PAMs were included. Thus, eight final models, two models per cluster
1, 2, 4, and 5 PAMs, were selected.
SIFt analysis. Structural Interaction Fingerprints (SIFt) were used to map the allosteric
binding site of GABAB2 subunit in the eight selected homology models [46,47]. The residues
around each docked ligand and the type of interaction was determined based on distance (cut-
off 4Å) and atom/residue type (and angle in case of hydrogen bonds), and for every accepted
ligand-residue interaction, the appropriate fingerprint bits (any contact, backbone, side
chain, polar, hydrophobic, hydrogen bond donor, hydrogen bond acceptor, aromatic, and/or
charged) were turned on [47]. A SIFt is hence a binary pattern describing interactions between
Allosteric modulation of the GABAB receptor
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all amino acids in contact with a ligand. SIFts describing the interactions of individual ligands
in the GABAB allosteric binding pocket were averaged into SIFt profiles based on different
input taking only the ’any contact’ bit into account and applying a cutoff of 50% (default set-
tings) [47]. Two general 2D-SIFT profiles, SIFt(8) and SIFt(7), were constructed. While SIFt
(8) was constructed based on the docking results of the PAMs in clusters 1, 2, 4, and 5 in their
respective models (mGlu- and rhodopsin-based models), SIFt(7) was based solely on the dock-
ing results of the cluster 1, 2, 4, and 5 PAMs in the seven mGlu-based models. In addition,
three template-specific 2D-SIFt profiles were generated based on docking results in the rho-
dopsin-based model (input: one model—cluster 1 PAMs, SIFt(1U19)), mGlu1-based models
(input: two models—cluster 4 PAMs, SIFt(4OR2)), and mGlu5-based models (input: five mod-
els—cluster 1, 2, and 5 PAMs, SIFt(4OO9)). Finally, three cluster-specific 2D-SIFt profiles
were constructed based on the docking of the PAMs in clusters 1 (input: one rhodopsin- and
one mGlu5-based model, SIFt(C1)), cluster 2 (input: two mGlu5-based models, SIFt(C2)), and
cluster 5 (two mGlu5-based models, SIFt(C5)). SIFt(C4) was generated based on cluster 4
PAMs and was hence identical with SIFt(4OR2).
GPCR family C numbering scheme
The GPCR database class C (GPCRdb(C)) numbering scheme [48] is used in the paper to facil-
itate comparison between class C receptors. A sequence-based scheme, where the first digit
refers to the TM helix, the second digit to the position of the amino acid in relation to the most
conserved amino acid of the helix and the third digit, separated by x, corrects for helical bulges
and constrictions [48], is used. The amino acid in position 3.50x50, for instance, is the most
conserved amino acid in TM3.
Results
In the present study, homology models of the GABAB2 subunit containing the allosteric bind-
ing pocket of the GABAB receptor have been constructed using x-ray crystal structure tem-
plates from GPCR classes A, B, and C. The results of the amino acid sequence alignment of
templates and target showed that the sequence identity between the 7TM domain GABAB2
subunit and the class A and B crystal structures was ranging between 10% and 13% but
increased significantly between GABAB2 subunit and the class C members mGlu1 and mGlu5
(19% and 22%, respectively) (S1 Fig). The 7TM sequence similarity between GABAB2 subunit
and the class A and B templates were ranging from 28% to 34%, and more than 40% for the
class C templates (S1 Fig).
Through iterative steps of homology modelling and docking analysis of five clusters of
PAMs vs. decoys, the number of GABAB2 homology models was reduced from the initial 600
models, via 456 induced-fit models, to eight final GABAB2 homology models (S5 Table). These
models are available as supporting information (S1–S8 Models). The results showed that seven
of the eight models originated from class C x-ray crystal structure templates (two mGlu1- and
five mGlu5-based models), while the last model was constructed based on rhodopsin template
(S5 Table). The GABAB2 models based on the class A β2-AR (PDB id 2RH1) and class B CRF1
receptor (PDB id 4K5Y) were outperformed by the models based on rhodopsin and the mGlu
receptors in the docking of PAMs versus decoys (S4 Table). For GABAB2 homology models
based on the class B human glucagon receptor (PDB id 4L6R), no representative orientations
of the PAMs could be selected and no IFD optimisation was hence performed.
The ability of the constructed models to enrich positive allosteric modulators among signif-
icantly higher numbers of decoys when docked into the putative allosteric binding site was
used for selection of eight final GABAB2 homology models. The eight final GABAB2 models
Allosteric modulation of the GABAB receptor
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were chosen by selecting two models based the docking of each cluster of PAMs except the
cluster 3 PAMs (S4 Table). Analysis of the docking results of cluster 3 PAMs showed that the
best enrichment of the active ligands were in GABAB2 homology models constructed based
on class B CRF1 receptor (PDB id 4K5Y) (S4 Table), though no models were selected due
to the low BEDROC scores (< 0.5; S4 Table). However, all 13 cluster 3 PAMs docked into
the two selected mGlu1-based models and one of the selected mGlu5-based model (model
C2_M1_4OO9), though the scores of the cluster 3 PAMs in these models (and hence the BED-
ROC values) were not as good as the scores of the cluster 4 and 2 PAMs docked into these
models, respectively (S5 Table). Visual inspection of the docking results showed that the best
orientations of the cluster 3 PAMs were in the mGlu1-based models, but more variation in
the binding orientations of the ligands were seen than for the cluster 4 PAMs in these models
(results not shown). The cluster 3 PAMs also docked in the rhodopsin-based model; however,
visual inspection of the results showed that multiple of the ligands were docked outside the
binding site.
To map the allosteric binding site of GABAB2 subunit based on the docking results of the
PAMs, structural interaction fingerprint (SIFt) profiles were generated (Table 1, S6 Table.
Fig 4). The general SIFt profile (SIFt(8)) revealed that 24 amino acids in TMs 3, 5, 6, and 7
were within 4 Å of more than 50% of the ligands in clusters 1, 2, 4, and 5 PAMs in the eight
GABAB2 models (Table 1), while one additional residue was identified in the SIFt(7) general
Table 1. Putative GABAB2 allosteric binding site. SIFt(8), SIFt(7) profiles and corresponding amino acids in GABAB2 subunit and mGlu1 and mGlu5
receptors. GPCRdb(C), GPCR database numbering. Amino acids in bold have been shown to change binding/potency of allosteric ligands > 5-fold when
mutated in other class C human receptors (data extracted from GPCRdb [5,6] accessed Nov. 25, 2015).
GPCRdb(C) GABAB2 mGlu1 mGlu5 SIFt(8) SIFt(7)
3.33x33 T557 R661 R648 0.67 0.74
3.36x36 L560 V664 I651 1 1
3.37x37 T561 G665 G652 0.7 0.67
3.40x40 Y564 S668 P655 1 1
3.41x41 T565 A669 A656 0.62 0.58
3.44x44 F568 Y672 Y659 0.71 0.79
5.39x39 W656 G752 G739 0.6 0.56
5.40x40 L657 V753 V740 0.9 1
5.43x43 V660 P756 P743 0.63 0.68
5.44x44 Y661 L757 L744 0.9 1
5.47x47 K664 N760 N747 0.99 1
5.48x48 G665 G761 G748 0.57 0.63
5.50x50 L667 L763 L750 0.46 0.52
5.51x51 M668 I764 I751 0.75 0.83
6.46x46 V699 T794 T781 0.9 1
6.49x49 M702 I797 I784 1 1
6.50x50 C703 W798 W785 1 1
6.53x53 G706 F801 F788 0.97 0.96
6.54x54 A707 V802 V789 0.9 0.88
6.57x57 S710 Y805 Y792 1 1
7.31x32 I723 T814 T801 0.68 0.75
7.32x33 V724 T815 M802 1 1
7.35x36 V727 A818 S805 0.9 1
7.36x37 I728 V819 V806 0.69 0.65
7.39x40 C731 S822 S809 0.98 1
https://doi.org/10.1371/journal.pone.0173889.t001
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profile constructed using only the mGlu-based models (Table 1). Of the 24 SIFt(8) amino
acids, nine ’hotspot’ residues (defined as residues with SIFt(8) values 0.95) were identified,
while four additional hotspots were observed when excluding the docking results in the rho-
dopsin-based models from the analysis (SIFt(7), Table 1). The results also showed that the
GABAB2 allosteric binding site was hydrophobic in nature; only ten of the putative allosteric
binding site amino acids were polar or charged, the majority of which were located in TMs 3
and 5 (Table 1).
The models selected based on the docking of the cluster 1 PAMs were the only models
selected that had been constructed based on different templates, namely the class A rhodopsin
(PDB id 1U19) and class C mGlu5 receptor (PDB id 4OO9). In comparison to the mGlu-based
models, the ligands docked closer to the extracellular environment in the rhodopsin-based
model (Fig 5, S2 Fig). In the rhodopsin-based model, the side chain of N650EL2 formed hydro-
gen bonds to the–NO2 moieties of the cluster 1 PAMs and the side chain of S710
6.57x57 was in
hydrogen bonding distance of the protonated nitrogen ligand moieties (S2 Fig). In compari-
son, possible hydrogen bonds between the ligand–NO2 moieties and/or protonated nitrogen
moieties and M7026.49x49 and G7066.53x53 backbone atoms, located deeper in the allosteric
binding pocket, were observed in the mGlu5-based model (Fig 5).
Fig 4. Putative GABAB2 allosteric binding pocket. (A) The 7TM domain of model c1_m2_4009 (mGlu5-based model) with putative allosteric binding site
shown as orange mesh. (B) Location of the allosteric binding site identified through docking of PAMs shown in model c1_m2_4009 (mGlu5-based model).
Hotspot residues shown in bold/italics (SIFt(8) hotspots) and bold/italics/underlined (SIFt(7) hotspots) (Table 1). The figure has been generated using ICM
software version 3.8–0 [49].
https://doi.org/10.1371/journal.pone.0173889.g004
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Fig 5. PAM docking poses. (A) Cluster 1 PAMs in model c1_m2_4OO9 (mGlu5-based model), (B) cluster 2 PAMs in model c2_m1_4OO9
(mGlu5-based model), (C) cluster 4 PAMs in model c4_m2_4OR2 (mGlu1-based model), and (D) cluster 5 PAMs in model c5_m1_4OO9
(mGlu5-based model). Intermolecular hydrogen bonds shown as dotted lines. Images generated using ICM software version 3.8–0 [49].
https://doi.org/10.1371/journal.pone.0173889.g005
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Though the 3D structures of the models were more conserved among the seven mGlu-based
models than between the rhodopsin- and mGlu-based models, significant differences were also
observed between the mGlu-based GABAB2 models. Superposition of the models revealed
minor horizontal shifts in the TMs around the putative allosteric binding site, especially in TMs
5, 6 and 7 (S3 Fig). TM6 was moreover partly unwound in the allosteric binding site region in
the mGlu5-based models selected based on docking of cluster 1 and 5 PAMs (Fig 5, S2 and S3
Figs). Several significant differences were also observed in the orientations of the amino acids
constituting the putative allosteric binding site of the mGlu-based GABAB2 models (Fig 5, S2
Fig). In particular, the orientations of the side chains of Y5643.40x40 and K6645.47x47 varied sig-
nificantly between the models, and in some models, the K6645.47x47 charged side chain pointed
away from the ligands in the binding site (Fig 5, S2 Fig). Differences in the location of TM6
amino acids in the putative allosteric binding site were also observed, mainly reflecting differ-
ences in unwinding and/or horizontal shifts in TM6 in this region (Fig 5, S2 and S3 Figs). How-
ever, visual inspection of the docking results also showed that commonly observed interactions
between the PAMs and the amino acids of the GABAB2 allosteric binding site were perpendicu-
lar and/or sandwich stacking interactions between the ligands and the aromatic side chain of
Y5643.40x40 and/or Y6615.44x44 (Fig 5, S2 Fig). Backbone and/or side chain interactions with
amino acids K6645.47x47 and M7026.49x49, C7036.50x50, and G7066.53x53 were also observed with
multiple of the docked PAMs, while hydrophobic interactions with amino acids in all four TMs
contributing to the allosteric binding site were also common with all PAMs (Fig 5, S2 Fig).
Discussion
Within the last 10 years, critical advances in the experimental characterisation of GPCRs have
led to the determination of multiple class A receptors in different activation states [50] and the
first structure bound to a G-protein [51]. In addition, the first structures of class B, C, and F
members were recently published [31,52–55]. The majority of the currently available struc-
tures are of class A GPCRs, and it has been estimated that more than 60% of the members of
class A can be predicted using the homology modelling technique given a minimum of 30%
TM sequence identity with one of the available crystal structures [56]. Assessment of the accu-
racy of homology modelling of membrane proteins has indicated that a sequence identity of
approx. 30% may yield a transmembrane region Cα-RMSD to the native of 2 Å or less, pro-
vided that an accurate template-target sequence alignment can be achieved [57]. The impor-
tance of template-target sequence alignment on the quality of homology models was also
recently highlighted in the GPCR dock 2013 assessment [58]. The class F smoothened (SMO)
receptor shared a sequence identity of approx. 14% with the closest template available and the
GPCR dock 2013 results showed that the median 7TM and binding pocket RMSD for the
SMO receptor in complex with the ligand SANT-1 were 6.33 Å and 10.66 Å, respectively [58].
Hence, despite the recent releases of x-ray crystal structures of more closely related GPCRs to
the GABAB receptor, homology modelling of the GABAB2 subunit was still highly challenging.
In the current study, the template-target alignments were adjusted based on structural infor-
mation from six x-ray crystal structure templates. The overall 7TM sequence identity between
GABAB2 subunit and its closest homologues, the mGlu1 and mGlu5 receptors, was approx.
20%, significantly higher than for the class A and B templates (approx. 10%-13%) (S1 Fig). The
results of this study also unambiguously show that GABAB2 homology models constructed
using class C templates were the best to enrich the known PAMs–seven of eight final models
were based on the two class C templates.
To predict the 3D structure of the GABAB2 TM domain, MODELLER software [33] was
chosen to scan the conformational space of GABAB2 subunit and to decrease the ligand bias
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inherited from the selected templates. The ability of the models to enrich known GABAB
receptor PAMs that had been grouped into 5 diverse clusters based on ligand structure (S1
Table) among significantly higher number of decoys was used to guide the selection of
GABAB2 homology models. Different conformations of the GABAB2 subunit specific for
each cluster of PAM were thus obtained. Initially, docking was performed into the 600 crude
GABAB2 models (i.e., 100 models/template), followed by optimisation of the models using the
induced-fit docking approach in which rigid receptor docking was combined with protein
structure prediction and refinement [59], and redocking of the PAM-decoy sets. The ligand-
guided homology modelling approach hence combined IFD and docking of actives vs. decoys
(virtual ligand screening enrichment), approaches that have successfully been applied to gener-
ate high-quality homology models of other GPCRs [60]. The approach is also in line with
multiple other studies showing the importance of incorporating ligand information and exper-
imental knowledge into homology modelling protocols. Different approaches have previously
successfully been used, ranging from receptor-ligand restraints to different IFD and ligand-
steered docking protocols [61–64].
A challenge of the ligand-guided homology modelling of GABAB2 subunit was, however,
the relatively low number and limited structural diversity of the currently known GABAB allo-
steric modulators (S1 Table). The activities of the available PAMs had, moreover, been evalu-
ated using different types of in vitro functional assays and/or using different concentrations of
GABA (10 nM, 1000 nM, 10.000 nM, not always given in the literature) (S1 Table). EC50 values
were not available for all modulators (S1 Table), and in case of the cluster 4 PAMs, all ligands
except ADX71943 were retrieved from patent literature and only an EC50 range of each PAM
was hence available (< 100 nM, 100–500 nM, 500–1000 nM) (S1 Table).
Site-directed mutagenesis data can be highly useful when evaluating homology models
and docking results. For the GABAB receptor, only one site-directed mutagenesis study that
describes the effects of mutations of amino acids of the 7TM domain of the GABAB2 subunit
from rat has been published [14]. However, mutations of several of the putative allosteric bind-
ing site residues identified through docking of the PAMs in the present study (Table 1) was
shown to affect the ability of the positive modulator GS39783 (cluster 1) to activate the rat
GABAB receptor [14]. The site-directed mutagenesis data, for instance, showed that the rat
GABAB2 G706T
6.53x53/A708P6.55x55/S710T6.57x57 triple mutant conferred agonistic activity to
GS39783 (cluster 1 PAM) and CGP7930 (cluster 5 PAM) in absence of GABA [14]. In the pres-
ent study, G7066.53x53 and S7106.57x57 were within 4 Å of the majority of the PAMs in all eight
final models (Table 1), while A7086.55x55 pointed away from the binding pocket (helical turn)
and was not identified as being part of the allosteric binding pocket. Comparison of the mGlu-
based GABAB2 homology models revealed a horizontal movement of the extracellular part of
TM6 (S3 Fig) and showed that the helix was partly unwound in the region around G7066.53x53
in the mGlu5-based GABAB2 models selected through docking of cluster 1 and 5 PAMs (Fig 5,
S2 Fig). Glycine and proline residues are often found in TM regions that are unwound or con-
tain helical kinks, and movement of TM6 of GPCRs is known to play a pivotal role during
activation of the GPCRs [65]. The present results in combination with the rat GABAB2 site-
directed mutational data may thus indicate that the switch from positive modulation to agon-
ism of GS39783 and CGP7930 induced by the G706T6.53x53 and A708P6.55x55 mutations may
be the results of changes in the flexibility/movements of the extracellular part of TM6.
The docking results also indicated that hydrogen bonds between the -NO2 moiety of
GS39783 and other cluster 1 PAMs and the backbone of G7066.53x53 may be formed (Fig 5, S2
Fig). Due to the structural differences between GS39783 (cluster 1 PAM) and CGP7930 (clus-
ter 5 PAM) (Fig 3, S1 Table), the docking results in contrast suggested that interactions with
K6645.47x47 (currently not mutated in GABAB receptor) may be more important for binding of
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the CGP7930 and the other cluster 3 PAMs than hydrogen bonding interactions with TM6 res-
idues (Fig 5, S2 Fig). This may provide an explanation to why the obtained agonistic efficacy
of CGP7930 in the G706T6.53x53/A708P6.55x55/S710T6.57x57 and G706T6.53x53/A708P6.55x55 rat
GABAB2 mutants, was only approx. 25% of the response obtained with GS39783 [14]. Interest-
ingly, the docking results also showed that a hydrophobic ligand moiety of PAMs in clusters 1
and 5 were located in the vicinity of S7106.57x57 (Fig 5, S2 Fig), providing an explanation to
why the S710T6.57x57 mutation was not necessary to confer agonistic activity of the two PAMs
[14].
Considerably more site-directed mutagenesis data is available from studies on the other
class C members than GABAB receptor. Though extrapolation of mutagenesis data from other
class C members is extremely difficult due to the very low sequence identity between the class
members, it is clear that mutations of amino acids at certain positions in the TM helices give
significant changes in ligand binding or potency across multiple class C members [5,6]. Muta-
tions that result in> 5-fold changes in ligand binding/potency in one or more class C mem-
bers are highlighted in Table 1. Of the nine hotspot amino acids identified by docking of the
PAMs into the eight GABAB2 models based on the mGlu and rhodopsin templates (Fig 4,
Table 1), mutations of amino acids in the corresponding positions have been shown to give
significant changes in other class C GPCRs except for position 6.49x49—corresponding to
M7026.49x49 in GABAB2 subunit (Table 1). In case of the four additional hotspots from SIFt(7)
analysis, residues in two of the positions, L6575.40x40 and Y6615.44x44, have been mutated and
shown to significantly affect ligand potency in other class C GPCRs, while V6996.46x46 and
V7277.35x36 have not (Table 1).
Though the overall sequence identity may be relatively low between GPCRs, the sequence
identity is usually significantly higher in the orthosteric binding sites of the receptors. From a
homology modelling perspective, higher sequence identity is positive as the quality of the mod-
els in binding site region thus usually improves. From a pharmacological point of view, how-
ever, the increased conservation of the orthosteric binding pocket is challenging as it makes
development of selective ligands more difficult, and this is one of the major reasons why devel-
opment of allosteric modulators is highly interesting. In line with this, comparison between
the 24 (25) amino acids identified through docking of known PAMs to constitute the putative
GABAB receptor allosteric binding site and the corresponding residues in mGlu1 and mGlu5
receptors showed little sequence identity, though the overall sequence similarities were signifi-
cantly higher (33% and 38% for mGlu1 and mGlu5, respectively) (Table 1). Comparison of the
GABAB2 (Table 1) and mGlu 1–8 receptor allosteric binding sites as reported by Doré et al.
[43] highlighted several similarities and differences between the receptors. In total, 16 com-
mon amino acid positions were identified between the GABAB2 and mGlu 1–8 receptor allo-
steric binding sites (Table 1, [43]). Amino acids in several of these positions shared common
characteristics; hydrophobic amino acids were found corresponding to L5603.36x36, L6675.50x50,
M6685.51x51, M7026.49x49, V7247.32x33 (except T/mGlu1), and I7287.36x37, while the amino acids
in positions F5683.44x44 and C7317.39x40 were aromatic and polar, respectively (Table 1, [43]).
In contrast, the amino acids corresponding to T5613.37x37, Y6615.44x44, V6996.46x46, C7036.50x50,
G7066.53x53, and V7277.35x36 were highly conserved between the mGlu 1–8 receptors but were
non-conserved between the mGlu receptors and GABAB2, whereas the amino acids corre-
sponding to Y5643.40x40, V6605.43x43, and K6645.47x47 varied among all nine receptors (Table 1,
[43]). Interestingly, multiple of the amino acids identified in the current work to be important
for binding of the PAMs to GABAB2 subunit, were located in these variable positions—includ-
ing Y5643.40x40 (P, S, F, or T in mGlu receptors) and Y6615.44x44 (L in all mGlu receptors),
K6645.47x47 (N, D, or S in mGlu receptors), C7036.50x50 (W in all mGlu receptors), and
G7066.53x53 (F in all mGlu receptors). In addition, one of the identified SIFt(8) hotspot amino
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acid positions, S7106.57x57, was not part of the mGlu receptor allosteric binding site [43]. The
corresponding amino acids in this position in the mGlu receptors are aromatic in nature [43].
Likewise, the residue in the position corresponding to the SIFt(7) hotspot L657, 5.40x40, was
not included in the mGlu receptor allosteric binding sites [43]. The results of this study hence
indicate that design of selective GABAB receptor allosteric modulators is possible.
Conclusions
In the present study, the first atomic-resolution description of the GABAB2 putative allosteric
binding site in complex with positive allosteric modulators have been determined through
homology modelling and docking of positive allosteric modulators. Analysis of the docking
results and comparison with mutagenesis data from GABAB and other human class C GPCRs
highlight several interesting differences between the homologous receptors and suggest several
residues that may infer ligand selectivity. The eight GABAB receptor homology models gener-
ated moreover enriched the known active PAMs before presumably inactive compounds and
may hence be useful tools in virtual screening campaigns to discover new allosteric modula-
tors. Despite no models being selected based on the docking of cluster 3 PAMs, these PAMs
also docked into the two mGlu1-based models selected through docking of the cluster 4 PAMs
and one of the cluster 2 mGlu5-based models, indicating that the current eight models also
may be used to identify analogues of cluster 3 PAMs in virtual screening campaigns. The eight
models constructed in the present study may thus aid the discovery of novel GABAB receptor
allosteric modulators through screening and the structure-based design and optimisation of
GABAB allosteric modulators.
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